1
|
Rahim AB, Lim HK, Tan CYR, Jia L, Leo VI, Uemura T, Hardman-Smart J, Common JEA, Lim TC, Bellanger S, Paus R, Igarashi K, Yang H, Vardy LA. The Polyamine Regulator AMD1 Upregulates Spermine Levels to Drive Epidermal Differentiation. J Invest Dermatol 2021; 141:2178-2188.e6. [PMID: 33984347 DOI: 10.1016/j.jid.2021.01.039] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 01/15/2021] [Accepted: 01/27/2021] [Indexed: 12/29/2022]
Abstract
Maintaining tissue homeostasis depends on a balance between cell proliferation, differentiation, and apoptosis. Within the epidermis, the levels of the polyamines putrescine, spermidine, and spermine are altered in many different skin conditions, yet their role in epidermal tissue homeostasis is poorly understood. We identify the polyamine regulator, Adenosylmethionine decarboxylase 1 (AMD1), as a crucial regulator of keratinocyte (KC) differentiation. AMD1 protein is upregulated on differentiation and is highly expressed in the suprabasal layers of the human epidermis. During KC differentiation, elevated AMD1 promotes decreased putrescine and increased spermine levels. Knockdown or inhibition of AMD1 results in reduced spermine levels and inhibition of KC differentiation. Supplementing AMD1-knockdown KCs with exogenous spermidine or spermine rescued aberrant differentiation. We show that the polyamine shift is critical for the regulation of key transcription factors and signaling proteins that drive KC differentiation, including KLF4 and ZNF750. These findings show that human KCs use controlled changes in polyamine levels to modulate gene expression to drive cellular behavior changes. Modulation of polyamine levels during epidermal differentiation could impact skin barrier formation or can be used in the treatment of hyperproliferative skin disorders.
Collapse
Affiliation(s)
- Anisa B Rahim
- Skin Research Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore
| | - Hui Kheng Lim
- Skin Research Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore
| | - Christina Yan Ru Tan
- Skin Research Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore
| | - Li Jia
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
| | - Vonny Ivon Leo
- Skin Research Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore
| | - Takeshi Uemura
- Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan
| | - Jonathan Hardman-Smart
- Centre for Dermatology Research, School of Biology, University of Manchester, Manchester, United Kingdom; NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; St John's Institute of Dermatology, King's College London, London, United Kingdom
| | - John E A Common
- Skin Research Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore
| | - Thiam Chye Lim
- Division of Plastic, Reconstructive & Aesthetic Surgery, Department of Surgery, National University Hospital, National University of Singapore, Singapore, Singapore
| | - Sophie Bellanger
- Skin Research Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore
| | - Ralf Paus
- Centre for Dermatology Research, School of Biology, University of Manchester, Manchester, United Kingdom; NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom; Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA
| | - Kazuei Igarashi
- Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan
| | - Henry Yang
- Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
| | - Leah A Vardy
- Skin Research Institute of Singapore, Agency for Science, Technology and Research (A∗STAR), Singapore, Singapore.
| |
Collapse
|
2
|
Insight into the Metabolite Pattern of Psoriasis: Correlation among Homocysteine, Methionine, and Polyamines. Symmetry (Basel) 2021. [DOI: 10.3390/sym13040606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Psoriasis is an incurable dermatological disorder, characterized by increased epidermal cell proliferation. Numerous studies have focused on the modulation of polyamine (PA) metabolism in psoriatic lesions, as well as the relationship between serum homocysteine (Hcy) levels and psoriasis severity. The correlation between Hcy and PA levels has not been investigated, although both of them depend on methionine (Met) loading. The aim of this study was to examine Met, Hcy, and polyamine levels in serum, saliva, lesions, and non-affected skin to investigate the eventual relationship between their levels in skin samples and to assess the correlation of each metabolite among the tested samples. This study was conducted on 24 patients with plaque-form psoriasis vulgaris. The original LC-MS/MS method was used for quantification of analytes. Hyperhomocysteinemia was observed and the serum levels of spermidine (Spd) and spermine (Spm) were also found to be elevated. A significant increase in Met (p < 0.05) and Spm (p < 0.001) concentrations in the psoriatic plaques were found, when compared to the non-affected skin. Significant correlations were established between all polyamines levels and between methionine and spermine in both types of cutaneous samples. This study illustrates the tight relationship between Met and Polyamine levels in epidermis of psoriatic patients. Our results could be helpful in psoriasis treatment, highlighting the importance of the balanced protein diet and intake of vitamins B12 and B9.
Collapse
|
3
|
Hyperproliferation is the main driver of metabolomic changes in psoriasis lesional skin. Sci Rep 2020; 10:3081. [PMID: 32080291 PMCID: PMC7033101 DOI: 10.1038/s41598-020-59996-z] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2019] [Accepted: 02/06/2020] [Indexed: 11/15/2022] Open
Abstract
Systematic understanding of the metabolite signature of diseases may lead to a closer understanding of the disease pathogenesis and ultimately to the development of novel therapies and diagnostic tools. Here we compared for the first time the full metabolomic profiles of lesional and non-lesional skin biopsies obtained from plaque psoriasis patients and skin samples of healthy controls. Significant differences in the concentration levels of 29 metabolites were identified that provide several novel insights into the metabolic pathways of psoriatic lesions. The metabolomic profile of the lesional psoriatic skin is mainly characterized by hallmarks of increased cell proliferation. As no significant differences were identified between non-lesional skin and healthy controls we conclude that local inflammatory process that drives the increased cell proliferation is the main cause of the identified metabolomic shifts.
Collapse
|
4
|
Wang Q, Wang YL, Wang K, Yang JL, Cao CY. Polyamine analog TBP inhibits proliferation of human K562 chronic myelogenous leukemia cells by induced apoptosis. Oncol Lett 2014; 9:278-282. [PMID: 25435975 PMCID: PMC4246664 DOI: 10.3892/ol.2014.2615] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Accepted: 09/22/2014] [Indexed: 12/23/2022] Open
Abstract
The aim of the present study was to investigate the effects of the novel polyamine analog tetrabutyl propanediamine (TBP) on the growth of K562 chronic myelogenous leukemia (CML) cells and the underlying mechanism of these effects. MTT was used for the analysis of cell proliferation and flow cytometry was performed to analyze cell cycle distribution. DNA fragmentation analysis and Annexin V/propidium iodide double staining were used to identify apoptotic cells. The activity of the key enzymes in polyamine catabolism was detected using chemiluminescence. TBP can induce apoptosis and significantly inhibit K562 cell proliferation in a time- and dose-dependent manner. TBP treatment significantly induced the enzyme activity of spermine oxidase and acetylpolyamine oxidase in K562 cells, and also enhanced the inhibitory effect of the antitumor drug doxorubicin on K562 cell proliferation. As a novel polyamine analog, TBP significantly inhibited proliferation and induced apoptosis in K562 cells by upregulating the activity of the key enzymes in the polyamine catabolic pathways. TBP also increased the sensitivity of the K562 cells to the antitumor drug doxorubicin. These data indicate an important potential value of TBP for clinical therapy of human CML.
Collapse
Affiliation(s)
- Qing Wang
- Institute of Molecular Biology, Medical College, China Three Gorges University, Yichang, Hubei 443002, P.R. China
| | - Yan-Lin Wang
- Institute of Molecular Biology, Medical College, China Three Gorges University, Yichang, Hubei 443002, P.R. China
| | - Kai Wang
- College of Chemical and Pharmacy, Wuhan Engineering University, Wuhan, Hubei 430073, P.R. China
| | - Jian-Lin Yang
- Institute of Molecular Biology, Medical College, China Three Gorges University, Yichang, Hubei 443002, P.R. China
| | - Chun-Yu Cao
- Institute of Molecular Biology, Medical College, China Three Gorges University, Yichang, Hubei 443002, P.R. China
| |
Collapse
|
5
|
Zhu W, Li J, Su J, Li J, Li J, Deng B, Shi Q, Zhou Y, Chen X. FOS-like antigen 1 is highly expressed in human psoriasis tissues and promotes the growth of HaCaT cells in vitro. Mol Med Rep 2014; 10:2489-94. [PMID: 25175497 DOI: 10.3892/mmr.2014.2509] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Accepted: 06/26/2014] [Indexed: 11/06/2022] Open
Abstract
Psoriasis is a multifactorial disease and the mechanisms involved in its pathogenesis remain to be elucidated. FOS‑like antigen 1 (Fra‑1) is a proto‑oncogene. It is a negative inhibitor of activator protein‑1 activity and possesses transforming activity. The effect of and possible mechanisms underlying Fra‑1 in psoriasis remain to be elucidated. In the present study, western blot analysis and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) techniques were used to identify differentially expressed Fra‑1 in psoriatic and in normal control tissues. Compared with the control samples, the expression of normalized Fra‑1 genes in psoriasis was 12.6 times higher. Western blot analysis was used to assess the protein levels of Fra‑1. The results demonstrated that the protein expression of Fra-1 was high in tissues affected by psoriasis. This also corresponded with the results of RT‑qPCR. Fra‑1‑stable expressing HaCaT/Fra‑1 or control HaCaT/vector cell lines were then generated to elucidate the function of Fra‑1 in the growth of HaCaT cells. The results demonstrated that Fra‑1 promoted the growth of HaCaT cells in vitro by arresting the cell cycle and inhibiting cell apoptosis. These results suggested that Fra‑1 may be important in psoriasis.
Collapse
Affiliation(s)
- Wu Zhu
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
| | - Jing Li
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
| | - Juan Su
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
| | - Jie Li
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
| | - Jinmao Li
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
| | - Bo Deng
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
| | - Qian Shi
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
| | - Yanhong Zhou
- Molecular Genetics Laboratory, Cancer Research Institute, Central South University, Changsha, Hunan 410078, P.R. China
| | - Xiang Chen
- Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
| |
Collapse
|